Chiltern International Ltd. Appoints Andrew Monaghan, PhD, Director, Global Pharmacovigilance

LONDON and WILMINGTON, N.C., July 24, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announces the appointment of Andrew Monaghan, PhD, as Director, Global Pharmacovigilance.

In his role of Director, Global Pharmacovigilance Andrew Monaghan will lead the Chiltern Pharmacovigilance team and expand the organization's global pharmacovigilance offering.

Andrew has more than 30 years' experience in clinical research and development among top pharmaceutical companies, most recently as global head of safety operations at Roche Products, UK where he led and managed 500 safety operations staff across 7 locations globally and delivered the business safety compliance goals.

Sharon Moore, MD, Executive Vice President, Global Medical and Regulatory Affairs, commented: "We are excited to have Andrew join Chiltern's Pharmacovigilance team. His strong leadership skills and extensive clinical experience will ensure our clients continue to receive customized and efficient safety solutions to meet their specific product and regulatory requirements, whether with investigational or postmarketed products."

Andrew's experience includes leading the clinical development of two major products and managing several products through regulatory submission and approval. He has worked in the USA and France in Regulatory Affairs and was the global head of study management and data management groups. Andrew's experience spans the major therapeutic areas.

Andrew has been responsible for devising strategies related to organizational design, process improvement and the implementation of new technologies, as well as implementation management. Andrew holds B.Sc and PhD degrees in Biochemistry from the University College Cardiff, United Kingdom. Andrew is based in the UK.

Company profile

About Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,600 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. For further information: www.chiltern.com.

SOURCE Chiltern